Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) reported Q2 EPS of ($0.25), $0.06 worse than the analyst estimate of ($0.19). Revenue for the quarter came in at $20.9 million versus the consensus estimate of $20.81 million.

For earnings history and earnings-related data on Alnylam Pharmaceuticals, Inc. (ALNY) click here.

Earnings